Intravesical therapy of noninvasive bladder tumors (stage Ta) with doxorubicin and urokinase.
A double-blind investigation was done on 44 patients with noninvasive bladder tumors (stage Ta) given randomized intravesical treatment with doxorubicin with or without urokinase. The bladder tumors were not removed before treatment in any patient. No significant difference in response was detected between the 2 types of treatment. Of the patients 86 per cent responded to treatment, including 52 per cent who achieved complete remission. At 12 and 42 months after termination of treatment 42 and 35 per cent of the patients, respectively, remained free of recurrent tumor.
D000368:Aged; D003556:Cystitis / Q000139:chemically induced; D004311:Double-Blind Method; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011897:Random Allocation; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects
D004317:Doxorubicin; D014568:Urokinase-Type Plasminogen Activator